Skip to content
left end
left end
right end

Dr Karin Bradley

Name:   Dr Karin Bradley Karin Bradley
Current Post:  

Consultant Endocrinologist, University Hospitals Bristol
Honorary Senior Clinical Lecturer, University of Bristol
Specialties:  

Endocrinology
General Medicine
Medical qualifications:  

BSc MBBS FRCP D.Phil.(Oxon)

 
Date of registration:   GMC full registration 1997
Membership of professional bodies:  

2011: Fellow Royal College of Physicians
2007: UK and Ireland Neuroendocrine Tumour Society
2006: European Society for Endocrinology
2002: American Endocrine Society
2000: Society for Endocrinology

 

 

 

 

 
Special clinical interests:  

Neuroendocrinology
Endocrine genetic syndromes
Endocrine Late effects of childhood cancer
Antenatal endocrinology
Endocrinology in a critical care setting

 
Professional profile/background:  

I am Clinical Lead for Endocrinology with clinical specialist interests in neuroendocrinology, endocrine genetic syndromes, endocrine late effects of childhood cancer, antenatal endocrinology and endocrinology in a critical care setting. I chair the regional UH Bristol Neuroendocrine MDT.

In addition, I have University of Bristol funded academic sessions and have secured both funding and ethical approval for my initial programme of research to study the HPA axis in various critical illness scenarios. I am also a successful co-applicant on a three year MRC grant (PI Professor Stafford Lightman) to deliver research studies in patients with Addison's disease and Congenital Adrenal Hyperplasia.

I contribute to the specialty at a national level through a variety of roles including being a PACES examiner, being an elected member of the Editorial Board of Clinical Endocrinology, being the elected Media Representative of the Public Engagement Committee of the Society for Endocrinology and since 2010 co-organising two very successful annual regional endocrine meetings - the SW Endocrine Symposium and the BBCO (Bristol, Birmingham, Cardiff and Oxford) Neuroendocrine Meeting.

 

 
Web links to any published articles: .
Manuscripts and textbook chapters (Excluding abstracts) since 2005 
  1. Bradley KJ. External Senior Reviewer for Chapters on Neuroendocrine Tumours and Genetic Endocrine Syndromes. Oxford Handbook of Endocrinology and Diabetes. Oxford University Press. Third Edition. In Press
  2. Raghavan R, Taylor PN, Bhake R, VaidyaB, Martino E, Bartalena L, Dayan CM,Bradley KJ.Amiodarone Induced Thyrotoxicosis, an overview of UK management. Clinical Endocrinology 2012. 77(6): 936-7.
  3. Raghavan R &Bradley KJ. Hypopituitarism. GP Newspaper 2011.
  4. Bradley KJ. Chapters on Neuroendocrine Tumours and Genetic Endocrine Syndromes. Oxford Handbook of Endocrinology and Diabetes. Oxford University Press. Second Edition. Edited by JAH Wass and HE Turner. 2009
  5. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge C, Patmanidi AL, Kennedy AM, Loh NY & Thakker RV. PARAFIBROMIN is a nuclear protein with a functional monopartite NLS. Oncogene 2006. 26: 1213-1221.
  6. Bradley KJ& Thakker RV. The Hyperparathyroidism-Jaw Tumour Syndrome. Clinical Cases in Bone & Mineral Metabolism 2006. 3(2) 167-174.
  7. Bradley KJ.Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, da Conceição Pereira M, Davie MWJ, Dudley N, Leite V, Sadler G, Seller A & Thakker RV. PARAFIBROMIN mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clinical Endocrinology (Oxf) 2006: 64(3): 299-306.
  8. Bradley KJ.Pituitary Incidentalomas. Clinical Endocrine Oncology. Blackwell Publishing. Second Edition 2006. Edited by JAH Wass and I Hay.
  9. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young A & Thakker RV. Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated hyperparathyroidism. Journal of Medical Genetics 2005: 42: e51 
  10. Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE, Laidler P, Manek S, Robbins CM, Salti IS, Thompson NW, Jackson C. & Thakker RV. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. Journal of Internal Medicine 2005: 257(1): 18-26.